{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-017114","form_type":"8-K/A","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2022-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.969470+00:00","generated_at":"2026-06-25T01:53:06.467706+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Cardiff Oncology shareholders reject advisory vote on executive compensation at 2022 annual meeting","bullets":["Corrected voting results show say-on-pay failed: 7.93M For, 7.36M Against, 2.02M Abstain, 12.06M broker non-vote.","All seven director nominees elected; BDO USA ratified as auditor; amendment to 2021 Omnibus Equity Plan approved.","Amendment filed to correct original 8-K error in Proposal 4 (advisory vote on executive compensation) results."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-017114","json":"https://secwatch.observer/filing/0001628280-22-017114.json","markdown":"https://secwatch.observer/filing/0001628280-22-017114.md","text":"https://secwatch.observer/filing/0001628280-22-017114.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000162828022017114/0001628280-22-017114-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000162828022017114/crdf-20220609.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T01:53:06.467706+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}